BRPI0518426A2 - composiÇÕes farmacÊuticas compreendendo fenofibratos e sistemas solventes - Google Patents

composiÇÕes farmacÊuticas compreendendo fenofibratos e sistemas solventes

Info

Publication number
BRPI0518426A2
BRPI0518426A2 BRPI0518426-6A BRPI0518426A BRPI0518426A2 BR PI0518426 A2 BRPI0518426 A2 BR PI0518426A2 BR PI0518426 A BRPI0518426 A BR PI0518426A BR PI0518426 A2 BRPI0518426 A2 BR PI0518426A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
fenofibrates
solvent systems
fenofibrate
solvent system
Prior art date
Application number
BRPI0518426-6A
Other languages
English (en)
Inventor
George Bobotas
Roelof M L Rongen
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of BRPI0518426A2 publication Critical patent/BRPI0518426A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÕES FARMACÊUTICAS COMPREENDENDO FENOFIBRATOS E SISTEMAS SOLVENTES. A presente invenção refere-se a composições farmacêuticas em forma de dose de unidade de fenofibrato e um sistema de solvente de ésteres de ácido graxo, no qual o fenofibrato é substancialmente dissolvido no sistema de solvente
BRPI0518426-6A 2004-12-06 2005-12-05 composiÇÕes farmacÊuticas compreendendo fenofibratos e sistemas solventes BRPI0518426A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63312604P 2004-12-06 2004-12-06
PCT/US2005/044036 WO2006062933A2 (en) 2004-12-06 2005-12-05 Stable compositions of fenofibrate with fatty acid esters

Publications (1)

Publication Number Publication Date
BRPI0518426A2 true BRPI0518426A2 (pt) 2008-11-25

Family

ID=36578470

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518426-6A BRPI0518426A2 (pt) 2004-12-06 2005-12-05 composiÇÕes farmacÊuticas compreendendo fenofibratos e sistemas solventes

Country Status (12)

Country Link
US (1) US20060188529A1 (pt)
EP (1) EP1830804A2 (pt)
JP (1) JP2008522972A (pt)
KR (1) KR20070098855A (pt)
CN (1) CN101094647A (pt)
AU (1) AU2005314197A1 (pt)
BR (1) BRPI0518426A2 (pt)
CA (1) CA2589656A1 (pt)
EA (1) EA200701228A1 (pt)
MX (1) MX2007006775A (pt)
NO (1) NO20073457L (pt)
WO (1) WO2006062933A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008516890A (ja) * 2004-08-06 2008-05-22 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なフェノフィブラート製剤および関連治療方法
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
CN102307576A (zh) 2008-12-15 2012-01-04 班纳制药公司 用于增强水不溶性活性剂的释放和吸收的方法
NZ594236A (en) * 2009-01-26 2014-08-29 Univ Taipei Medical Use of pterosin compounds for treating diabetes and obesity
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
AU2013277441B2 (en) 2012-06-17 2017-07-06 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
DE69842121D1 (de) * 1997-12-10 2011-03-17 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
US6814977B1 (en) * 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US7014864B1 (en) * 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
CA2355820A1 (en) * 1998-12-18 2000-06-29 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
WO2000057918A2 (en) * 1999-03-31 2000-10-05 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US6372251B2 (en) * 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability

Also Published As

Publication number Publication date
CN101094647A (zh) 2007-12-26
MX2007006775A (es) 2008-02-25
NO20073457L (no) 2007-09-05
KR20070098855A (ko) 2007-10-05
AU2005314197A1 (en) 2006-06-15
EP1830804A2 (en) 2007-09-12
EA200701228A1 (ru) 2007-12-28
CA2589656A1 (en) 2006-06-15
WO2006062933A2 (en) 2006-06-15
JP2008522972A (ja) 2008-07-03
US20060188529A1 (en) 2006-08-24
WO2006062933A3 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
BRPI0518426A2 (pt) composiÇÕes farmacÊuticas compreendendo fenofibratos e sistemas solventes
AR054507A1 (es) Sistema transdermico de vareniclina
CL2018003398A1 (es) Composición farmacéutica de liberación sostenida que comprende micro-partículas. (divisional de solicitud 2013-03538).
BRPI0507897B8 (pt) formulação de droga sólida
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
CL2017000669A1 (es) Forma de dosificación farmacéutica (divisional de la solicitud 1029/2014)
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
EP1730163A4 (en) Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
EA200900260A1 (ru) Гранулы и орально дезинтегрируемые таблетки, содержащие оксикодон
BRPI0716196A2 (pt) Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos.
FR2898356B1 (fr) Diesters d'acides carboxylique ramifies
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
DK1814534T3 (da) Derivater af 5-aminolevulinsyre til behandling af acne
BRPI0606339A2 (pt) formas farmacêuticas resistentes a álcool
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
GT201000144A (es) " composiciones farmaceuticas "
BRPI0810350A2 (pt) "conjunto conector para predeterminados sistemas".
BRPI0620229A8 (pt) formulação
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
FR2983409B1 (fr) Comprime susceptible de lutter contre le detournement par voie injectable
NZ592647A (en) Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester
CL2007003232A1 (es) Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
AR059357A1 (es) Formulaciones farmaceuticas
CY1108231T1 (el) Σταθερη στερεα δοσολογικη μορφη περιλαμβανουσα δεσμοπρεσσινη

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.